AESARA

What AESARA does

AESARA is a digital-forward Value & Access consulting firm serving biopharmaceutical companies across the United States and Europe. Founded in 2016 by Sissi Pham as a woman- and minority-owned business, the firm is headquartered in Chapel Hill, NC with a wholly-owned European subsidiary (AESARA Europe Ltd.) in London, and operates as a virtual company with 50+ professionals across multiple geographies. The firm's core offerings span three pillars: Access Strategies (Value & Access strategy, payer research and advisory boards, value proposition and communication tools, HTA submissions), Value Strategies (integrated evidence generation planning, real-world evidence strategy, economic modeling, clinical outcome assessment, global value dossiers), and Management Consulting (organization design, vision and competency development, education and training). Supporting products include the AESARA HEOR Benchmarking Report 2024, the ATLAS AI-enabled value-mapping platform (developed by affiliated company Arysana), and the European HTA Submission Programme. AESARA also invests in pipeline development through a two-year PharmD fellowship with the UNC Eshelman School of Pharmacy and a Visiting Scientist program.

AESARA generates revenue primarily through project-based professional services engagements — long-tail biopharma consulting contracts priced on scope — supplemented by time-and-materials advisory support and one-time/perpetual licenses for benchmarking reports (enterprise-wide access priced at $49K). The firm sells through a direct, enterprise-field-sales model with dedicated US and Europe Strategic Partnership leads managing account relationships. Customer concentration sits primarily in global pharmaceutical organizations (including 13 of the top 20), with additional mid-cap biotech, US clinical-stage biotech, and European specialty pharma clients. Engagement scope spans launch and lifecycle support, integrated evidence planning, HEOR strategy, payer-engagement tooling, value-based pricing, European access including HTA submissions, and organizational transformation for internal Market Access and HEOR functions.

The firm's go-to-market relies on thought leadership (ISPOR conference presence, blog, "Change Before Change" podcast, webinars, LinkedIn) and on elite talent sourced from GSK, Pfizer, AbbVie, Novartis, Vertex, Eli Lilly, Takeda Oncology, Boehringer Ingelheim, and other large-pharma market access organizations — a bench that underpins its positioning as a "disruptive consultancy." AESARA holds ISO certification, leads the cross-industry CFL-SASS collaborative with ISPOR and NPC (supported by 15 major pharmaceutical companies), and operates formal Centers of Excellence in rare diseases and oncology. The company is privately held and bootstrapped, with no external funding rounds disclosed.

Name

AESARA

Legal name

AESARA Inc.

Website

https://aesara.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

AESARA is a digital-forward Value & Access consulting firm serving biopharmaceutical companies. It delivers market access strategy, HEOR, HTA submissions, and organizational consulting, supported by an AI-enabled platform and a 50+ person team across the US and Europe.

Ownership category

akta.pro rank

Headquarters

HQ city

Chapel Hill

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Strategic Consulting Services: Project-based consulting engagements for Value & Access strategy, HEOR, market access, and management consulting services delivered to biopharmaceutical companies.
2. Time & Materials Support: On-demand expert support from AESARA available at short notice, providing temporary staffing with experienced HEOR professionals to cover client needs.
3. HEOR Benchmarking Reports: License-based access to industry benchmarking reports providing insights on HEOR organizations, with enterprise-wide access pricing at $49K.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

AESARA is a digital-forward Value & Access consulting agency that delivers strategic consulting services to biopharmaceutical companies across market access, pricing, HEOR (Health Economics and Outcomes Research), and Medical Affairs. The firm supports clients through project-based engagements covering Value & Access strategy, payer research and advisory boards, HTA submissions, evidence generation planning, real-world evidence strategy, economic modeling, value communication tools, and management consulting for organizational transformation. AESARA also sells a licensed industry benchmarking report on HEOR organizations.

Product overview

AESARA is a digital-forward Value & Access agency offering a comprehensive suite of consulting services for biotech and pharma companies. The core offerings include three interconnected service pillars: Access Strategies (Value & Access Strategy, Payer Research, HTA Submissions, Value Communication Tools), Value Strategies (Evidence Generation Planning, RWE Strategy, Economic Modeling, Patient Perspective), and Management Consulting (Education, Organization Design, KPI Development). Supporting these are specialized products including the AESARA HEOR Benchmarking Report, European HTA Submission Programme via AI-enabled ATLAS platform, and educational programs (PharmD Fellowship, Visiting Scientist, and Internship Programs). AESARA also deploys generative AI capabilities for FAQ document generation, article summarization, chatbot creation, and plain language summaries to enhance client deliverables.

Differentiator

Problem solved

Functional benefit

Products and services

• Market Access Strategy Services Comprehensive consulting services helping biotech and pharma optimize patient access and reimbursement through evidence-based strategic thinking across market access, pricing, HEOR, and medical affairs.
• Access Strategies Consulting services including Value & Access Strategy development, Payer Research & Advisory Boards, Value Proposition development, Value Communication Tools, HTA Submissions, Endpoint Strategy, and Value-based Agreements.
• Value Strategies Services focused on evidence demonstration including Integrated Evidence Generation Planning (IEGP), Comprehensive Patient Perspective, Literature Reviews, Global Value and Evidence Dossiers, Economic Modeling, RWE Strategy & Study Design, and Clinical Outcome Assessment (COA) Strategy.
• Management Consulting Organizational consulting including Education & Training, Purpose/Vision/Strategy development, People/Talent/Culture enhancement, Technology/Enablers/KPI development, and Organization Structure/Process/Roles design.
• AESARA HEOR Benchmarking Report 2024 Licensed benchmarking report providing insights on biopharma HEOR organizations, including organization structure and positioning, team characteristics, capabilities and infrastructure, and ways of working, with AESARA insights and recommendations; priced at $49K for enterprise-wide access.
• AESARA Europe Specialized European market access consulting covering European Landscape Assessment, HTA Decision Analysis, EU Joint Scientific Consultation, European pricing strategy, EU JCA dossier development, and European Launch Management.
• European HTA Submission Programme Planning and execution of health technology assessment (HTA), price, and reimbursement submissions in European markets using AI-enabled ATLAS platform for dossier development.
• PDAB Policy Solutions & Engagement Comprehensive support for Prescription Drug Affordability Boards including policy scanning, educational resource creation, and evidence-based communication tailored to client needs.
• AI Use Cases for Value & Access Consulting services deploying generative AI tools including ChatGPT, Claude, and Gemini for FAQ document generation, table recreation from images, chatbot creation, article summarization, and plain language summary generation to support Value & Access client deliverables.
• PharmD Fellowship Program Two-year postdoctoral fellowship program in collaboration with UNC Eshelman School of Pharmacy focused on Market Access and Health Informatics, sponsored through DPOP/PACE.
• Visiting Scientist Program One-year accelerated professional development program for soon-to-be PharmD or PhD graduates seeking industry or consulting experience.
• AESARA Internship Program Internship programs for current students and recent graduates including MBA Intern, Graduate Intern, Student Intern, and AESARA iDX Intern positions.

Quantifiable outcome

• Supported over 60 product launches since founding in 2016
• +3 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• ISPORcoreStrategic or Co-development Partner · 1 April 2026AESARA serves as ISPOR's trusted advisor, modeling agility and creativity while operating within the competitive landscape. The company leads landmark initiatives such as the CFL-SASS collaborative. ISPOR CEO Rob Abbott provided endorsement of AESARA's work in shaping health policy worldwide.
• National Pharmaceutical Council (NPC)coreStrategic or Co-development Partner · 1 April 2026Cross-industry collaboration with NPC to address industry challenges in demonstrating and communicating the value of innovation. NPC supports the CFL-SASS collaborative report for real-world evidence in promotion.
• CFL-SASS Collaborative Partners (15 Pharmaceutical Companies)coreStrategic or Co-development Partner · 1 April 2026Industry roadmap initiative for use of real-world evidence in promotion, supported by 15 major pharmaceutical companies along with ISPOR and NPC. AESARA is leading this collaborative that nobody else stepped up to do.
• ArysanacoreTechnology or IntegrationAESARA uses ATLAS, an AI-enabled software platform developed by Arysana (affiliated company), for mapping value messages, evidence and activities. This platform replaces traditional global value dossiers, providing flexible, tailored strategy management.
• University of North Carolina Eshelman School of PharmacycoreStrategic or Co-development PartnerTwo-year fellowship program in collaboration with UNC focused on Market Access and Health Informatics. Part of the DPOP/PACE fellowship program. The program sponsors pharmacy students pursuing MS degrees for practical industry experience.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• McKinsey & Company (Pharma Practice): McKinsey serves the world's largest pharma companies on market access, pricing and commercial strategy. Competes with AESARA on top-20 pharma accounts but offers broader management consulting breadth and global teams.
• Boston Consulting Group (Pharma Practice): BCG's healthcare and pharma practice covers market access, pricing and value strategy for biopharma clients. Comparable in addressing top-tier pharma HEOR and access needs, but with broader generalist consulting scale than AESARA.
• IQVIA: IQVIA is the largest life sciences services and consulting platform, with extensive market access, HEOR and real-world evidence capabilities. Overlaps AESARA across strategy consulting, evidence generation and HTA support, but at vastly greater scale and with broader service breadth.

Direct peers

• ZS Associates: ZS is a major management consulting firm with a deep life sciences practice covering market access, HEOR, pricing and commercial strategy for global pharma. Comparable to AESARA in therapeutic-area expertise, project-based model, and emphasis on data-driven value-and-access work.
• Putnam Associates: Putnam is a specialized life sciences strategy consulting firm focused on pricing, market access and reimbursement for biopharma. Closely aligned with AESARA's Access Strategies and HEOR offerings and similar in client base (top global pharma and emerging biotech).
• ClearView Healthcare Partners: ClearView is a boutique consulting firm focused on strategy and value, access and pricing work for biopharma. Directly comparable to AESARA in size, therapeutic-area focus, and project-based delivery to top pharma and biotech clients.
• Evidera (PPD): Evidera is a dedicated HEOR, market access and real-world evidence consulting arm within PPD/Thermo Fisher. Directly comparable to AESARA in HEOR, economic modeling and HTA submission services for global biopharma, with broader scale.

Emerging players

• Alira Health: Alira Health is a global healthcare consulting firm offering market access, HEOR, RWE and patient-centric evidence services. Comparable to AESARA in scope of value-and-access services and target client base of pharma and emerging biotech.
• Charles River Associates: CRA's Life Sciences practice provides consulting on pricing, market access, HEOR and commercial strategy for biopharma. Overlaps AESARA on value-and-access engagements and is similarly positioned with mid-sized pharma and biotech clients.

Others

• Definitive Healthcare: Definitive Healthcare provides commercial intelligence and analytics for healthcare and biopharma, intersecting AESARA's market access and evidence-generation work through data and benchmarking products used by similar pharma clients.

Market position

Weaknesses3 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/aesara
• LinkedInlinkedin.com/company/aesara

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AESARA